18.12.2017

BIH Mini Symposium LIQUID BIOPSY: FROM BENCH TO BEDSIDE

Liquid biopsy holds the promise for cancer patient stratification, prediction of treatment response and cancer resistance with the goal of changing the clinical focus to tailored treatments. The BIH Genomics Core Facility offers a novel non-invasive liquid biopsy assay based on the detection of circulating tumor DNA (ctDNA).

This mini symposium will be held in English.

OVERVIEW

Participants will be familiarized with approaches to detect and analyze ctDNA. The clinical benefits and limitations of liquid biopsy-based diagnostics will be discussed.

AUDIENCE

This mini symposium targets all scientists and clinicians interested in the field of liquid biopsies, who wish to learn about the benefits and challenges of the approach.

AGENDA

09:15 – 09:30 Introduction & Welcome

Tomasz Zemojtel, Head of BIH Genomics Core Facility
Gregor Obernosterer, Roche Diagnostics Germany

09:30 – 10:15 Clinical applications and challenges of liquid biopsy

Andre Rosenthal, Signature Diagnostics, Potsdam

10:15 – 11:00 Liquid biopsy as a diagnostic tool

Max Ma, Roche Sequencing Solutions, Pleasanton, USA

11:00 – 11:30 Bioinformatics challenges in data analyses

Sebastian Froehler, Signature Diagnostics, Potsdam

11:30 – 12:00 Open Forum


Please register at eventsbihealth.de